Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) have been assigned a consensus rating of “Buy” from the six brokerages that are presently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have updated their coverage on […]
OP-3136 demonstrated potent anti-tumor activity alone and in combination with both palazestrant and CDK4/6 inhibitors in preclinical ER+ breast cancer models Initiating IND-enabling studies with goal.
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 6,650,000 shares, an increase of 27.6% from the November 30th total of 5,210,000 shares. Based on an average daily volume of 777,800 shares, […]
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) was the recipient of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 6,650,000 shares, a growth of 27.6% from the November 30th total of 5,210,000 shares. Based on an average daily volume of 777,800 shares, […]